LEQEMBI® (lecanemab) EISAI HK Reg. No. HK-68289 (03 Jul, 2024) & HK-68290 (03 Jul, 2024) Composition: 3 LEQEMBI® is an amyloid beta-directed antibody with the active ingredient lecanemab-irmb. It is administered as an intravenous infusio...

INVEGA HAFYERA (paliperidone palmitate) JANSSEN Indications: INVEGA HAFYERA, an every-six-month injection, is indicated for the treatment of schizophrenia in adults after they have been adequately treated with: • A once-a-month paliperidone pal...